Four-year follow-up of two patients on maintenance therapy with fondaparinux and mycophenolate mofetil for microthrombotic antiphospholipid syndrome.
CONCLUSIONS: As described in our small cohort, patients with APS who suffer from microthrombotic arterial disease may benefit from maintenance therapy of anticoagulation with fondaparinux and immunosuppression with MMF, an approach which may be worthy of further trial. Fondaparinux does not require attention to diet, monitoring, and cumbersome bridging that is typical of warfarin therapy. MMF provides immunosuppression while sparing the side effects of steroid treatment.
PMID: 31122135 [PubMed - as supplied by publisher]
Source: Lupus - Category: Rheumatology Authors: Baron BW, Baron JM Tags: Lupus Source Type: research
More News: Antiphospholipid Syndrome | Coumadin | Diets | Hughes Syndrome | Lupus | Nutrition | Prednisone | Rheumatology | Warfarin